Skip to main content
Clinical Trials/IRCT20211020052819N2
IRCT20211020052819N2CompletedPhase 3

Evaluation of the effect of a natural product called 4 capsule plant based on Malus Domestica, Nigella Sativa, Peganum harmala, Terminalia chebula and vitamin C on clinical and laboratory, respiratory and prognostic symptoms of patients with Covid-19 virus

Artesh University of Medical Sciences0 sites100 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 70 years (—)
Sex
All

Inclusion Criteria

  • Admission for Covid patients, ranging in age from 18 to 70 years
  • without underlying disease (diabetes, hypertension, smoking, hyperlipidemia)
  • Positive PCR test for COVID-19

Exclusion Criteria

  • Patients with very large lung involvement and severe general condition and should be admitted to the intensive care unit.
  • Reluctance to continue the plan
  • Side effects that can cause the patient to stop the plan or leave the study after taking the supplement
  • Creating any unwanted digestive problems including heartburn, nausea, nausea, vomiting, diarrhea, etc.
  • Any allergies, whether skin, respiratory or other
  • Creating any side effects that did not exist before taking the supplement

Investigators

Sponsor
Artesh University of Medical Sciences

Similar Trials

Evaluation of the effect of a natural... | Clinical Trial